ICAMS investigators Profs John McMurray and Paddy Mark are part of landmark DAPA-CKD trial

The DAPA-CKD trial, led by  David Wheeler and Hiddo Heerspink, showed a statistically significant and clinically meaningful effect on its primary endpoint of a composite of worsening of renal function or risk of death AND met all its secondary endpoints in CKD, patients with and WITHOUT type-2 diabetes.

Farxiga met all primary and secondary endpoints in groundbreaking Phase III DAPA-CKD trial for the treatment of patients with chronic kidney disease

Press Release: https://astrazeneca.com/media-centre/press-releases/2020/farxiga-met-all-primary-and-secondary-endpoints-in-groundbreaking-phase-iii-dapa-ckd-trial-for-the-treatment-of-patients-with-chronic-kidney-disease.html

Is this the first medicine to significantly reduce the risk of death from any cause in patients with chronic kidney disease, a population with huge unmet medical need?

ICAMS investigators Profs John McMurray and Paddy Mark are proud to be part of this landmark trial and breakthrough in the treatment of patients with chronic kidney disease

The DAPA-CKD trial was presented at the ESC Congress 2020. The digital experience was held between Saturday, 29 August - Tuesday, 1 September and hosted a record 116,000 healthcare professionals from 211 countries.

Protocol image

Trial:Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

DAPA_CKD ESC twitter

DAPA_CKD ICAMS twitter

 
 

 

 


First published: 4 September 2020